Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2011-05-23
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the progression-free survival [PFS] at 36
months for patients with Hodgkin lymphoma who achieve a complete metabolic response as
demonstrated by a negative fluorodeoxyglucose (FDG)-PET scan after one cycle of ABVD
(adriamycin, bleomycin, vinblastine, dacarbazine) who undergo abbreviated ABVD chemotherapy
(3 cycles).